These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28875982)

  • 1. Cancer Immunotherapy: From local to global.
    Mulder WJM; Gnjatic S
    Nat Nanotechnol; 2017 Sep; 12(9):840-841. PubMed ID: 28875982
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
    Min Y; Roche KC; Tian S; Eblan MJ; McKinnon KP; Caster JM; Chai S; Herring LE; Zhang L; Zhang T; DeSimone JM; Tepper JE; Vincent BG; Serody JS; Wang AZ
    Nat Nanotechnol; 2017 Sep; 12(9):877-882. PubMed ID: 28650437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
    Ostrand-Rosenberg S
    Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis.
    Zhang P; Zhai Y; Cai Y; Zhao Y; Li Y
    Adv Mater; 2019 Dec; 31(49):e1904156. PubMed ID: 31566275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.
    Jonuleit H; Bopp T; Becker C
    Nanomedicine (Lond); 2016 Oct; 11(20):2699-2709. PubMed ID: 27654070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A brief glimpse over the horizon for type 1 diabetes nanotherapeutics.
    Garciafigueroa Y; Trucco M; Giannoukakis N
    Clin Immunol; 2015 Sep; 160(1):36-45. PubMed ID: 25817545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
    Goyvaerts C; Breckpot K
    J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-based immunotherapy for cancer.
    Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
    ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Listeria monocytogenes and its products as agents for cancer immunotherapy.
    Guirnalda P; Wood L; Paterson Y
    Adv Immunol; 2012; 113():81-118. PubMed ID: 22244580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-testis antigens in tumor biology and immunotherapy.
    Clark CE; Vonderheide RH
    Cancer Biol Ther; 2006 Sep; 5(9):1226-7. PubMed ID: 17021387
    [No Abstract]   [Full Text] [Related]  

  • 15. Recognition of tumor glycans by antigen-presenting cells.
    Aarnoudse CA; Garcia Vallejo JJ; Saeland E; van Kooyk Y
    Curr Opin Immunol; 2006 Feb; 18(1):105-11. PubMed ID: 16303292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy.
    Buabeid MA; Arafa EA; Murtaza G
    J Immunol Res; 2020; 2020():9624532. PubMed ID: 32377541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory Nanomedicine.
    Bartneck M
    Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28383783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Peptide-pulsed dendritic cell therapy].
    Takaue Y; Tanosaki R; Tobisu K
    Nihon Rinsho; 2000 Jul; 58 Suppl():295-8. PubMed ID: 11022733
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from immuno-oncology: a new era for cancer nanomedicine?
    Jiang W; Yuan H; Chan CK; von Roemeling CA; Yan Z; Weissman IL; Kim BYS
    Nat Rev Drug Discov; 2017 Jun; 16(6):369-370. PubMed ID: 28303024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.